Zebra‑Stripe Disease (Cutaneous Vasculitis)

Overview

Zebra‑stripe disease is a colloquial name for a form of cutaneous vasculitis that produces characteristic, alternating red‑purple and pale linear streaks on the skin, resembling a zebra’s coat. The condition results from inflammation of small‑to‑medium‑sized blood vessels in the dermis, leading to leakage of red blood cells and subsequent bruising patterns.

• Who it affects: Most cases occur in adults aged 30–60, with a slight female predominance (≈60 %).^[1]
• Prevalence: Cutaneous vasculitis overall affects about 15–30 per 100,000 people annually; the zebra‑stripe variant is rare, representing roughly 5–10 % of those cases.^[2]
• Geography: Reported worldwide; incidence is higher in temperate climates where viral infections and certain drug use are more common.

Symptoms

The presentation can be acute (days) or chronic (months). Symptoms may appear suddenly after a trigger or develop gradually.

Skin manifestations

• Linear purpura (red‑purple streaks) that follow the course of superficial blood vessels, often on legs, forearms, or trunk.
• Hypopigmented “zebra‑stripe” bands that appear as the purpura fade, creating alternating dark‑light patterns.
• Raised, palpable nodules or “papules” that may ulcerate.
• Warmth or tenderness over affected areas.
• Itching (pruritus) in up to 30 % of patients.

Systemic symptoms (when vasculitis extends beyond the skin)

• Low‑grade fever, chills.
• Fatigue, malaise.
• Joint pain or arthralgia (especially knees, ankles).
• Muscle aches (myalgia).
• Abdominal pain or gastrointestinal bleeding (rare).
• Kidney involvement – hematuria or proteinuria (≈5 % of cases).

Causes and Risk Factors

Cutaneous vasculitis is usually **immune‑mediated**, meaning the body's immune system mistakenly attacks its own blood vessels. Identifiable triggers are found in about 50–70 % of cases.

Common causes

• Infections – hepatitis B/C, HIV, streptococcal pharyngitis, bacterial endocarditis.^[3]
• Medications – antibiotics (penicillins, sulfonamides), non‑steroidal anti‑inflammatory drugs (NSAIDs), allopurinol, thiazide diuretics.^[4]
• Autoimmune diseases – systemic lupus erythematosus, rheumatoid arthritis, Sjögren’s syndrome.
• Malignancies – especially hematologic cancers (e.g., lymphoma, leukemia).
• Vaccinations – rarely, certain viral vaccines can trigger vasculitic reactions.

Risk factors

• History of prior vasculitic episodes.
• Chronic viral infection (HBV, HCV).
• Use of offending medications.
• Underlying autoimmune or connective‑tissue disease.
• Age > 50 (immune dysregulation increases with age).

Diagnosis

Diagnosing zebra‑stripe disease relies on a combination of clinical observation, laboratory work‑up, and sometimes skin biopsy.

Step‑by‑step approach

1. Clinical history and physical exam – documenting the pattern of lesions, recent infections, medication changes, systemic symptoms.
2. Laboratory tests:
   • Complete blood count (CBC) – may show leukocytosis or anemia.
   • Erythrocyte sedimentation rate (ESR) & C‑reactive protein (CRP) – inflammatory markers (often elevated).
   • Renal panel & urinalysis – to rule out kidney involvement.
   • Serologies: hepatitis B/C, HIV, ANA, ANCA, complement levels (C3, C4).
   • Blood cultures if infection is suspected.
3. Skin biopsy – 4‑mm punch from an active purpuric streak; histology shows leukocytoclastic vasculitis (neutrophilic infiltration, fibrinoid necrosis of vessel walls). Direct immunofluorescence can detect IgA, IgM, or complement deposition.
4. Imaging (if systemic disease is suspected) – chest X‑ray or CT, abdominal ultrasound, or echocardiography.

Diagnostic criteria (adapted from Chapel Hill Consensus)

• Palpable purpura + histologic evidence of small‑vessel vasculitis.
• Absence of another more likely cause (e.g., drug reaction, infection).
• When systemic involvement is present, additional organ‑specific criteria apply.

Treatment Options

Treatment is individualized based on severity, extent of skin involvement, and presence of systemic disease.

General measures

• Identify and remove the trigger (stop offending drug, treat infection).
• Rest and elevation of affected limbs to decrease edema.
• Compression stockings if lower‑extremity lesions are prominent.

Medications

1. Corticosteroids – first‑line for moderate‑to‑severe disease.
   • Prednisone 0.5–1 mg/kg/day, taper over 4–8 weeks.
   • Topical high‑potency steroids (clobetasol) for localized lesions.
2. Immunosuppressants (if steroids are contraindicated or disease recurs):
   • Azathioprine 2–3 mg/kg/day.
   • Mycophenolate mofetil 1–1.5 g twice daily.
   • Methotrexate 15–25 mg weekly (with folic acid).
3. Colchicine – 0.6 mg 2–3 times daily may reduce neutrophil activity, useful for mild disease.
4. Biologic therapy – For refractory cases, anti‑TNF agents (adalimumab, infliximab) or rituximab have shown benefit in small series.^[5]
5. Plasmapheresis – Reserved for severe, life‑threatening vasculitis with multi‑organ involvement.

Adjunctive care

• Analgesics (acetaminophen) for pain; avoid NSAIDs if they are the suspected trigger.
• Antihistamines for pruritus.
• Antibiotics if a bacterial infection is documented.

Living with Zebra‑Stripe Disease (Cutaneous Vasculitis)

While the visual appearance can be distressing, most patients lead normal lives with proper management.

Daily management tips

• Skin care – Gentle cleansing with mild soap; pat dry; apply fragrance‑free moisturizer.
• Sun protection – Use broad‑spectrum SPF 30+ sunscreen; sunburn can exacerbate lesions.
• Clothing – Soft, breathable fabrics; avoid tight bands that could impair circulation.
• Medication adherence – Take steroids exactly as prescribed; never stop abruptly.
• Monitor labs – Periodic CBC, liver function, and renal panels while on immunosuppressants.
• Exercise – Low‑impact activities (walking, swimming) improve circulation without stressing inflamed vessels.
• Stress reduction – Mindfulness, yoga, or counseling can help, as stress may trigger immune flares.
• Support networks – Join vasculitis patient groups (e.g., Vasculitis Foundation) for shared experiences.

Prevention

Because many triggers are modifiable, preventive strategies focus on reducing exposure.

• Review all medications with your physician annually; avoid known culprits.
• Maintain up‑to‑date vaccinations (influenza, pneumococcal) to lower infection risk.
• Practice good hygiene and promptly treat skin injuries or infections.
• Control chronic conditions: manage hypertension, diabetes, and hyperlipidemia.
• Limit alcohol and avoid illicit drug use, which can precipitate immune dysregulation.

Complications

If left untreated or inadequately controlled, cutaneous vasculitis can lead to:

• Permanent skin scarring or hyperpigmentation.
• Ulceration and secondary bacterial infection – may require debridement or antibiotics.
• Chronic pain or neuropathy due to nerve involvement.
• Systemic organ involvement – kidneys (glomerulonephritis), lungs (hemoptysis), gastrointestinal tract (ischemia, bleeding).
• Medication‑related adverse effects – steroid‑induced osteoporosis, cataracts, immunosuppressant toxicity.

When to Seek Emergency Care

---

References

1. Mayo Clinic. “Cutaneous vasculitis.” Updated 2023.
2. Jennette JC, et al. “2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides.” Arthritis & Rheumatology, 2013.
3. CDC. “Hepatitis B and C: Clinical manifestations.” 2022.
4. American College of Rheumatology. “Drug‑induced vasculitis.” 2021.
5. Wen et al. “Biologic therapy in refractory cutaneous vasculitis: a systematic review.” Rheumatology International, 2020.